Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Ofranergene obadenovec (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Sponsors VBL Therapeutics
- 19 Jun 2017 According to a VBL Therapeutics media release, long-term survival data from this trial will be presented at 2017 BIO International Convention.
- 19 Jun 2017 Long-term survival data from this trial published in a VBL Therapeutics Media Release.
- 21 Feb 2017 Results published in the VBL Therapeutics Media Release.